Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 341-346

  Demirer, T ^a   Buckner, C D ^a   Appelbaum, F R ^a   Lambert, K ^a   Bensinger, W I ^a   Clift, R ^a   Storb, R ^a   Slattery, J T ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia; Allo BMT; Bu CY; Chronic myeloid leukemia; TBI

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG TOXICITY; ERROR; FEMALE; GRAFT VERSUS HOST REACTION; HEART DISEASE; HUMAN; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE FRACTIONATION; RELAPSE; SKIN TOXICITY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; REPRODUCIBILITY OF RESULTS; WHOLE-BODY IRRADIATION;

EID: 0029927901     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Petersen FB, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplant 1989; 4: 617-623.
2. Lynch MHE, Petersen FB, Appelbaum FR et al. Phase II study of busulfan. cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995; 15: 59-64.
3. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
4. Lam W-C, Order SE, Thomas ED. Uniformity and standardization of single and opposing cobalt 60 sources for total body irradiation. Int J Radiat Oncol Biol Phys 1980; 6: 245-250.
5. Forman SJ, Blume KG, Krance RA et al. A prospective randomized study of acute graft-versus-host disease in 107 patients with leukemia: methotrexate/prednisone vs cyclosporine A/prednisone. Transplant Proc 1987; 19: 2605-2607.
6. Santos GW, Tutschka PJ, Brookmeyer R et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21-28.
7. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
8. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single center study. Blood 1995; 85: 3746-3753.
9. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
10. Crawford SW. Critical care and respiratory failure. In: Forman SJ. Blume K, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA. 1994, pp 513-526.
11. Shuhart MC, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 454-481.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Buckner CD, Clift RA, Appelbaum FR et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. Bone Marrow Transplant 1991; 7 (Suppl. 2): 6-8.
14. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723-1729.
15. Badger C, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation for acute leukemia in relapse. Leukemia Res 1982; 6: 383-387.
16. Gale RP, Horowitz MM. Bartin MM et al. IBMTR analysis of bone marrow transplants in acute leukemia. Bone Marrow Transplant 1989; 4: 83-84.
17. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with recurrent leukemia: a Southwest Oncology Group study. Blood 1993; 81: 2187-2193.
18. Hassan M, Oberg G, Ehrsson H. Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
19. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
20. Grochow LB. The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (Suppl. 4): 18-25.